Sector News

GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots

October 22, 2014
Life sciences
With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline–and, fittingly, for its top management ranks, too.
 
At the center: R&D chief Moncef Slaoui will shift over to chair the vaccines unit–soon to be bolstered by a $7.1 buyout of most of the Swiss pharma’s vaccines portfolio–effective immediately. Patrick Vallance, who had run R&D on a day-to-day basis, will be stepping in to take the reins.
 
Slaoui, who radically altered the British drugmaker’s drug development process with a reorg focused on small units of scientists, “will take more focused accountability for vaccines, ensuring we fully leverage the value of his knowledge and experience,” a GSK spokeswoman Mary Anne Rhyne told FiercePharma by email.
 
The move is part of an effort to “ensure that our leaders are focused and aligned” around pharmaceuticals, vaccines and consumer healthcare–another business that will get a boost from the Novartis swap as the companies team up on a joint venture. GSK’s consumer health president, Emma Walmsley, will be heading up that partnership, with Glaxo controlling a 63.5% stake.
 
On the pharma side, emerging markets chief Abbas Hussain–who, if you’ll recall, last year publicly apologized to China’s government and offered price cuts in penance for the company’s $489 million doctor bribery scandal–will assume the role of global pharmaceuticals president, and he’ll have North American pharma president Dierdre Connelly reporting to him, Rhyne said.
 
And they’ll have their work cut out for them: In the third quarter, Glaxo reported pharmaceutical sales down 12% in the U.S., thanks in part to an 18% respiratory plunge. Megablockbuster Advair powered that decline, with increased competition helping take a 25% bite out of the aging behemoth’s top-line haul.
 
By Carly Helfand
 

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.